SHR-1681
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 23, 2025
A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=300 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1